Nanosonics investors raise concerns before product launch
Shares of Nanosonics fell sharply after the latest earnings release, despite a announced $40 million share‑buyback and a near‑term rollout of its new endoscopy reprocessing device.
Market reaction eclipses earnings growth
The stock slid as much as 25 % on the day of the announcement, a move that analysts described as one of the toughest responses in the recent healthcare reporting cycle. Revenue for the year to 30 June 2026 rose 3 % to $203.9 million, while earnings before interest and taxes fell 10 % to $16 million. When adjusted for constant‑currency effects, revenue showed a 6 % increase to $211.5 million and EBIT rose 21 % to $21.6 million. The firm said the modest top‑line lift reflected stronger demand for its flagship disinfection system, but the earnings dip was linked to higher freight costs and tariff pressures.
Coris device poised for market entry
The upcoming launch targets the United Kingdom, Ireland and Australia, with a subsequent North American introduction. Management said early feedback from the controlled release has been positive, noting that the device tackles a persistent shortfall in current reprocessing methods, which can leave microscopic residue on flexible endoscopy probes. Pricing is expected to be three to five times that of the existing system, reflecting the advanced technology, and usage rates are projected at three to four times higher, potentially boosting consumable sales.
Related: ASX gains ground as Coles reports profit
In the reporting period the firm installed 4,230 new units, a 9 % increase that pushed the global installed base to 39,230 devices. The older platform generated $50.6 million of EBIT, up 16 % on a constant‑currency basis, and margins were described as “right up there with the best in the industry.”
The firm holds $155 million in cash at the end of June, a balance that should support the buy‑back and any opportunistic acquisitions. The announced repurchase follows a $20 million program completed the previous year.
Investors appear uneasy about the reliance on a single product line while the second product ramps up. The guidance for the current fiscal year projects revenue of $220‑228 million, an 8‑12 % rise, but expects gross margins to fall to 74‑76 % from 77.6 % due to tariff and freight headwinds.
From a broader perspective, the situation highlights the delicate balance firms face when expanding a portfolio around a core technology. Even with solid cash reserves and a clear growth path, market sentiment can turn sharply if investors doubt the timing or scale of new product adoption. This dynamic is especially pronounced in the medical‑device sector, where regulatory approvals and hospital procurement cycles add layers of uncertainty.
Related: Life Insurance Premiums: Where Does the Money Go
One factual note: the upcoming device will be installed in centralized reprocessing rooms rather than being dispersed throughout individual hospitals, a deployment model that could limit the total number of units compared with the legacy platform.
Despite the share decline, the firm’s CEO emphasized that the recent weather‑related slowdown in the U.S. Northeast was a temporary issue and that demand rebounded in the fourth quarter, suggesting no structural weakness in the business.
Looking ahead, the company’s ability to translate the projected higher utilization of the new equipment into sustained consumable revenue will be a key metric for investors. The next earnings release will likely reveal whether the anticipated “low single‑digit million” revenue from the device materializes and how it impacts overall profitability.
